Abstract

Background: Uric acid is an independent risk factor for cardiovascular disease. Hospital admission for ischemic heart disease (IHD) is increasing rapidly in our country. Although studies were conducted abroad regarding association of serum uric acid with in-hospital outcomes in patients with acute coronary syndrome (ACS), no data is yet available to show the association in our country. Objective: The objective of this study was to assess the association of serum uric acid level on admission with in-hospital outcomes of the patients with ACS. Materials and Methods: This cross sectional comparative study was done in the Department of Cardiology, Dhaka Medical College Hospital (DMCH) from January to December 2012. After proper ethical consideration total 93 ACS patients were enrolled in the study by nonrandom sampling. Serum uric acid of all subjects was measured within 24 hours of admission. Then in-hospital outcomes were observed in all subjects. Results: The frequency of hyperuricemia among ACS patients was 24.7% (22.54% in male and 31.82% in female). Hyperuricemic patients significantly developed heart failure (30.4% vs 11.4%, p=0.032) and conduction defect (13.0% vs 1.4%, p=0.017) than normouricemic subjects. The mean ejection fraction was significantly lower in hyperuricemic patients than patients with normal uric acid level (50.87 ± 10.27% vs 55.94 ± 6.66%). The mean ± SD duration of hospital stay of hyperuricemic group was significantly longer in patients with ACS (8.26 ± 1.18 vs 7.51±1.18 days, p=0.010). Conclusion: The measurement of serum uric acid level, an easily available and inexpensive biochemical tool, might turn out as a valuable risk marker for prediction of in-hospital outcomes in patients with ACS.

Key words: Serum uric acid; Ischemic heart disease; Acute coronary syndrome; Heart failure

Introduction

Coronary artery disease (CAD) is the most prevalent manifestation of cardiovascular disease and is associated with high mortality and morbidity. Among the CADs, acute coronary syndrome (encompassing ST-segment elevation myocardial infarction and unstable angina) is the leading cause of death in developed countries and second leading cause of death in developing countries and by the year 2020, CAD will hold the first place in the WHO’s list of leading cause
of disability. About 7.1 million deaths occurred globally in 1999 due to CAD and it will rise to 11.1 million by 2020. In the United Kingdom (UK), 1.3 million people develop CAD every year while in USA, 0.8 million people suffer from new heart attacks each year. Various studies have pointed out that South Asians have a higher prevalence of CAD as compared with other ethnicities with a higher rate at younger ages. In India, 4% rural and 11% urban populations suffer from CAD. Being a South Asian country Bangladesh is not immune to this higher prevalence of CAD. Atherosclerosis is the main pathology behind CAD and non-invasive methods for the prediction of the severity of atherosclerotic lesions have become an important objective for early treatment as well as primary preventive measures.

Acute coronary syndrome (ACS) is a common disease in Bangladesh. It causes a great cost in care and has significant morbidity and mortality. The progressively increasing trend of the disease in our country shows that the prevalence of CAD in our country was 3.3/1000 in 1976 and 17.2/1000 in 1986 indicating a 5 fold increase in 10 years. Ischemic heart disease (IHD) is becoming a significant burden on health care services in Bangladesh. The average prevalence of IHD from 3 small scale population-based studies in Bangladesh was 6.56/1000. Hospital admission for IHD is increasing rapidly in our country and the number of young patients having ACS has been increasing dramatically. Socioeconomic improvement and changes in lifestyle, increase in tobacco consumption and saturated fat intake, decrease in physical activity, increasing body weight and consequently increasing rate of diabetes mellitus (DM), hypertension (HTN) and dyslipidemia might have contributed to this increase in our population.

Uric acid is the final breakdown product of purine degradation in humans. Elevated serum uric acid has proved to be risk factor for ischemic heart disease and other cardiovascular diseases in several epidemiologic studies. It is also associated with increased death from cardiac causes. Experimental studies have shown a uric acid link to endothelial dysfunction, impaired oxidative metabolism, platelet adhesiveness and platelet aggregation. Uric acid is an independent risk factor for cardiovascular disease. It can exert its effect by several mechanisms. Studies in both in vitro and in animal models have raised some possibilities. Soluble concentrations of uric acid, when applied to vascular endothelial cells, inhibit the synthesis of nitric oxide in a dose-dependent manner. Uric acid also induces vascular smooth muscle proliferation in a dose-dependent manner. The combination of loss of the vasodilatory actions of nitric oxide, together with the proliferation of vascular smooth muscle, would appear to be a potent combination for constriction of the vascular bed.

Since the underlying pathophysiology of disease in patients with acute coronary syndrome (ACS) varies widely, accurate risk stratification to determine appropriate management and improve outcomes is essential. Increased serum uric acid levels are linked to obesity, dyslipidemia and hypertension (insulin resistance or syndrome X), all of which are also associated with increased risk for cardiovascular disease. However, the specific role of serum uric acid in this constellation remains uncertain. Several studies have investigated whether serum uric acid (SUA) is an independent marker of cardiovascular disease (CVD) risk. Most prospective studies found a positive association between SUA and CVD mortality as well as all-cause mortality.

Although studies were conducted abroad regarding association of SUA with in-hospital outcome in patients with ACS, no data is yet available to show the association in our country. So this study has been done on newly diagnosed ACS patients admitted in coronary care unit (CCU), Dhaka Medical College Hospital (DMCH), Dhaka to find out the association between on-admission serum uric acid level and in-hospital outcomes of these patients.

Materials and Methods
This cross sectional comparative study was conducted in the department of Cardiology, DMCH, Dhaka during the period of January to December 2012. A total of 93 patients from admitted ACS patients in the coronary care unit (CCU), DMCH within the study period were enrolled in the study by purposive sampling. The
patients who had history of previous myocardial infarction (MI), percutaneous transluminal coronary angiogram (PTCA), coronary artery bypass grafting (CABG), known cases of valvular heart disease or cardiomyopathy, patients taking drugs (pyrazinamide, ethambutol, diuretics, aspirin, alcohol), patients with serious co-morbid conditions (i.e. severe renal or liver dysfunction), history of gout, malignancies, psoriasis etc. were excluded from the study.

After admission various clinical presentations, severity and extent of ACS were documented. Traditional risk factors of ACS like smoking, hypertension, diabetes mellitus, dyslipidemia and family history of premature CAD were also documented.

Serum uric acid level was measured within 24 hours of admission. Patients with serum uric acid level >7 mg/dL in male and >6 mg/dL in female were placed in Group I and patients with serum uric acid ≤7 mg/dL in male and ≤6 mg/dL in female were placed in Group II.

The in-hospital outcomes (heart failure, arrhythmia, heart block, cardiogenic shock, cardiac arrest and mortality) and duration of hospital stay were compared between the two groups.

Statistical analysis

Data were analyzed by using SPSS for windows version 16.0. Categorical data were expressed as frequency and percentage and association between two variables were tested by using Pearson chi-square test. Continuous data were expressed as mean ± SD and difference of mean of two groups was determined by unpaired Student t test. Level of significance was set at 0.05.

Results

Among the total study subjects (N=93), 71 were male and 22 were female. The mean age of the study subjects was 57.43 ± 15.26 years. Out of them 23 (16 male and 7 female) were hyperuricemic. Table I shows the mean ± SD of serum uric acid levels of Group I (hyperuricemic group) and Group II (normouricemic group). It was significantly higher in Group I than in Group II (8.64 ± 2.24 mg/dL vs 5.22 ± 1.05 mg/dL, p<0.001).

The mean ± SD of ejection fraction of the patients of Group I and Group II were 50.87 ± 10.27% and 55.94 ± 6.66% respectively and the difference between them was statistically significant (p<0.05) (Table II). We found no significant difference in pulse rates, blood pressure and Hb levels between two groups.

The mean ± SD of fasting blood glucose was 7.62 ± 3.47 mmol/L in Group I and 6.64 ± 3.16 mmol/L in Group II with no statistical difference (p=0.208). The mean ± SD of serum creatinine was 1.93 ± 0.73 mg/dL in Group I and 1.32 ± 0.36 mg/dL in Group II. The serum creatinine level was significantly higher in hyperuricemic group (p<0.001). The mean ± SD of SGPT was 45.00 ± 8.75 IU/L in Group I and 40.81 ± 6.90 IU/L in Group II with no statistical difference (p=0.121). The mean ± SD of troponin I was 12.32 ± 13.74 ng/mL in Group I and 7.62 ± 11.68 ng/mL in Group II without any significant difference between two groups (p=0.112) (Table III).
Table III: Comparison of biochemical parameters between two groups (N=93)

| Biochemical parameters | Groups | p     |
|------------------------|--------|-------|
|                        | Group I (n=23) | Group II (n=70) |
| Fasting blood glucose level (mmol/L) | 7.62 ± 3.47 | 6.64 ± 3.16 | 0.208 NS |
| Serum creatinine (mg/dL) | 1.93 ± 0.73 | 1.32 ± 0.36 | <0.001 S |
| SGPT (IU/L) | 45.00 ± 8.75 | 40.81 ± 6.90 | 0.021 NS |
| Troponin I (ng/mL) | 12.32 ± 13.74 | 7.62 ± 11.68 | 0.072 NS |

Group I (hyperuricemic group), Patients with serum uric acid concentrations >7 mg/dL in men and >6 mg/dL in women; Group II (normal uric acid level group), Patients with serum uric acid concentrations ≤7 mg/dL in men and ≤6 mg/dL in women; p value derived from Student t test (for Troponin I Mann-Whitney U test). NS=Nonsignificant; S=Significant

Table IV: Comparison of lipid profiles between two groups (N=93)

| Parameters              | Groups | p     |
|-------------------------|--------|-------|
|                        | Group I (n=23) | Group II (n=70) |
| Total cholesterol (mg/dL) | 165.39 ± 41.07 | 179.14 ± 46.55 | 0.210 NS |
| LDL cholesterol (mg/dL) | 121.61 ± 39.21 | 124.83 ± 40.84 | 0.741 NS |
| HDL cholesterol (mg/dL) | 37.96 ± 8.06 | 36.19 ± 6.19 | 0.274 NS |
| Triglyceride (mg/dL) | 169.43 ± 88.20 | 166.11 ± 92.17 | 0.880 NS |

Group I (hyperuricemic group), Patients with serum uric acid concentrations >7 mg/dL in men and >6 mg/dL in women; Group II (normal uric acid level group), Patients with serum uric acid concentrations ≤7 mg/dL in men and ≤6 mg/dL in women; p value derived from Student t test; NS=Nonsignificant

Table V shows comparison of in-hospital outcomes between two groups. In patients of Group I development of heart failure and conduction defect was significantly higher compared to Group II patients (30.4% vs 11.4%, p=0.032 and 13.0% vs 1.4%, p=0.017 respectively). There was no significant difference in arrhythmia, cardiogenic shock, cardiac arrest and mortality between two groups.

Table V: Comparison of in-hospital outcomes between two groups (N=93)

| Individual in-hospital outcomes | Groups | p     |
|---------------------------------|--------|-------|
|                                | Group I (n=23) | Group II (n=70) | Total (n=93) |
| Heart failure (Number %)        | 7 (30.4%) | 8 (11.4%) | 15 (16.1%) | 0.032 S |
| Conduction defect (Number %)    | 3 (13.0%) | 1 (1.4%) | 4 (4.3%) | 0.017 S |
| Arrhythmias (AVFVT/VF) (Number %) | 1 (4.3%) | 5 (7.1%) | 6 (6.5%) | 0.636 NS |
| Cardiogenic shock (Number %)    | 1 (4.3%) | 3 (4.3%) | 4 (4.3%) | 0.990 NS |
| Cardiac arrest (Number %)       | 1 (4.3%) | 2 (2.9%) | 3 (3.2%) | 0.726 NS |
| Death (Number %)                | 2 (8.7%) | 3 (4.3%) | 5 (5.4%) | 0.416 NS |

Group I (hyperuricemic group), Patients with serum uric acid concentrations >7 mg/dL in men and >6 mg/dL in women; Group II (normal uric acid level group), Patients with serum uric acid concentrations ≤7 mg/dL in men and ≤6 mg/dL in women; p value derived from Pearson Chi-square test; NS=Nonsignificant; S=Significant

The mean ± SD of duration of hospital stay of Group I patients was 8.65 ± 0.98 days and that of Group II was 7.56 ± 1.76 days. Group I patients with ACS stayed at hospital for significantly more days than Group II patients (p=0.006) (Table VI).

Table VI: Comparison of duration of hospital stays between two groups of patients with ACS (N=93)

| Groups          | Mean hospital stay (days) | p     |
|-----------------|---------------------------|-------|
| Group I (n=23) | 8.65 ± 0.98               |       |
| Group II (n=70)| 7.56 ± 1.76               | 0.006 S |

Group I (hyperuricemic group), Patients with serum uric acid concentrations >7 mg/dL in men and >6 mg/dL in women; Group II (normal uric acid level group), Patients with serum uric acid concentrations ≤7 mg/dL in men and ≤6 mg/dL in women; p value derived from Student t test; S=Significant
Discussion

High SUA has been indicated as a risk factor for CAD and as an independent prognostic factor of poorer outcomes in patients with verified CAD.\textsuperscript{32-34} In our study, Group I (hyperuricemic) and Group II (normouricemic) had similar prevalence of traditional risk factors like smoking (\(p=0.846\)), hypertension (\(p=0.497\)), diabetes mellitus (\(p=0.142\)), dyslipidemia (\(p=0.245\)) and CAD (\(p=0.435\)).

The frequency of hyperuricemia among ACS patients in our study is 24.7% (22.54% in male and 31.82% in female). The frequency of hyperuricemia in our study is lower than the prevalence observed by Jularattanaporn et al\textsuperscript{35} which was 42.9%. The difference between two studies may be due to difference in sample size and food habit of the participants. Jularattanaporn et al enrolled only 49 Thai patients with acute coronary syndrome (ACS).

Baruah et al, Cheng et al and Nadkar & Jain found statistically significant higher uric acid level in patients with acute MI than age and sex matched healthy controls.\textsuperscript{36-38}

In this study we found that higher number of patients with hyperuricemia developed heart failure than patients with normal serum uric acid level (30.4% vs 11.4%, \(p=0.032\)). Similarly conduction defect was significantly more frequent in hyperuricemic group than normal uric acid level group (13.0% vs 1.4%, \(p=0.017\)). However, there were no significant differences in development of arrhythmia (4.3% vs 7.1%, \(p=0.636\)), cardiogenic shock (4.3% vs 4.3%, \(p=0.990\)), mortality (8.7% vs 4.3%, \(p=0.416\)) and cardiac arrest (4.3% vs 2.9%, \(p=0.723\)) between two groups.

The findings of our study are consistent with a number of studies abroad.\textsuperscript{39-44} In a recent study conducted in China Chen et al\textsuperscript{40} have shown that hyperuricemia patients had more in-hospital major adverse cardiac events (MACE) including heart failure, cardiogenic shock, acute renal failure and mortality compared with non-hyperuricemia patients (\(p<0.05\)). But there were no differences in rates of arrhythmia and atrioventricular block between the two groups (\(p>0.05\)).\textsuperscript{40} Kojima and co-workers evaluated 1,124 consecutive Japanese patients who were hospitalized within 48 hours of onset of symptoms of AMI and revealed that patients who developed short-term adverse events had high SUA concentrations. The study also suggested that hyperuricemia after AMI is associated with the development of heart failure.\textsuperscript{41} Kaya et al observed significantly higher hospital mortality, heart failure, and MACE in patients with high UA levels.\textsuperscript{42} Wu et al conducted a study with 3648 in-patients with high cardiovascular (CV) risk at baseline in Shanghai and Beijing and observed that patients in the lower and higher uric acid groups had increased cardiac and overall mortality risks compared with patients in the normal uric acid groups.\textsuperscript{43} Bae et al studied 660 consecutive patients with CAD, and they were followed-up for a mean of 27 months. They found that the highest uric acid level was a predictor of AMI, CHF and MACE.\textsuperscript{44} Krishnan et al collected data on 4,352 participants and revealed that patients in the highest quartile of uric acid had higher all-cause mortality, CHD mortality, and coronary incidence. They concluded that serum UA may be an independent prognostic marker for poor all-cause and CHD mortality in patients with recent acute MI.\textsuperscript{39}

Dharma et al enrolled 75 patients with acute STEMI in a cohort study. They found that STEMI patients with higher uric acid levels (>7.3 mg/dL) had increased rate of cardiovascular events compared with lower uric acid levels (<4.8 mg/dL).\textsuperscript{45} Framingham Heart Study found no significant association between SUA levels with CVD in either men or women after adjustment for other risk factors and diuretic use.\textsuperscript{27} Poullis suggested that the association of serum uric acid level with myocardial infarction, left ventricular dysfunction, and elevated inflammatory markers must be interpreted as an association, not a causal relation.\textsuperscript{46}

In our study 2 (8.7%) hyperuricemic patients and 3 (4.3%) normouricemic patients died during hospital stay. Though the short term mortality rate was higher in hyperuricemic patients than normouricemic group, the difference did not reach the level of significance (\(p=0.416\)). Our finding is similar with the finding of the study conducted by Jularattanaporn et al and Culleton et al.\textsuperscript{27,35} Jularattanaporn et al studied 49 patients with ACS and showed no significant difference in in-hospital adverse outcomes between hyperuricemic and normouricemic patients.\textsuperscript{35} Culleton et al reported that an elevated serum uric acid at baseline was not independently associated with increased risk of cardiovascular mortality.\textsuperscript{27} However, our findings were not supported by some published studies conducted by
Car & Trkulja, Fang & Alderman. Those studies included either a large number of patients or were conducted during a period of long time and allowed a long follow-up period. For these reasons their findings were not similar to our findings.

Car & Trkulja observed that higher SUA on admission was independently associated with higher in-hospital mortality and higher thirty-day mortality. They assessed 621 patients with AMI with ST elevation during a period of almost 5 years.

Fang & Alderman found that mortality from ischemic heart disease was significantly higher in age- and race-adjusted patients with highest quartile of uric acid level compared with the patients with lowest quartile of uric acid level for both men and women during 16.4 years of follow-up. They observed 77% increased death rate from ischemic heart disease in men and 3-fold increase in women with highest quartile serum uric acid level.

In our study, the patients of hyperuricemic group had to stay in hospital for significantly longer period than patients of normal uric acid level group (8.26 ± 1.18 days vs 7.51 ± 1.18 days, \( p=0.010 \)). Chen et al. did not support this. They showed the average stay in hospital was similar in both groups.

The present study provides evidence for positive association between elevated serum uric acid level on admission and poor in-hospital outcomes like heart failure, conduction defect and reduced ejection fraction in patients with ACS. The mean ± SD of hospital stay of hyperuricemic group was significantly longer than patients with normal uric acid level. The measurement of serum uric acid level, an easily available and inexpensive biochemical tool, might turn out as a valuable risk marker for prediction of in-hospital outcomes in patients with acute coronary syndrome.

References

1. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglyceride to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study. AM J Cardiol 1992; 70: 733–737.

2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.

3. Ahmed M, Majumder AAS, Rahman A, Baqui MA. Relationship between baseline white blood cell count and angiographic severity of coronary artery disease in patients with acute coronary syndrome. Bangladesh Heart Journal 2005; 20(1): 6–10.

4. Bangladesh Cardiac Society, 2004. ACS: Guideline for management (vol 5).

5. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37–45.

6. Hanak V, Munoz J, Teague J, Stanley AJR, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol 1992; 94: 219–222.

7. Sukonthasarn A. Prevention of coronary artery disease. In: Sukonthasarn A, Kuanprasert S (eds). New Guidelines in coronary artery disease. 1st edn. Chiang Mai: 2003: 3–33.

8. Malik A. Congenital and acquired heart disease. Bangladesh Med Res Coun Bull 1976; 11: 115–119.

9. Chowdhury AKMN, Alam MN, Ali SMK. Demography, morbidity and mortality in a rural community of Bangladesh. Bangladesh Med Res Coun Bull 1981; 7: 22–39.

10. Hussain A. Cardiovascular disease in the rural community in Bangladesh. Proceeding of the Bangladesh-Japan Joint Conference on Cardiac Diseases, January 31-February 1, 1984, Dhaka, Bangladesh: 168–171.

11. Islam MN, Ali MA, Ali M. Spectrum of cardiovascular diseases: the current scenario in Bangladesh. Bangladesh Heart J 2004; 19(1): 1–7.

12. Wortmann RL. Disorders of purine and pyrimidine metabolism. In: Kasper DL, Braunwald E, Fauci AS (eds). Harrison’s Principles of Internal Medicine. 16th edn. New York: McGraw-Hill, 2005: 2308–2313.

13. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. J Am Med Assoc 2000; 283: 2404–2410.

14. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 2006; 37: 1503–1507.

15. Wong KY, MacWalter RS, Fraser HW, Crombie I, Ogston SA, Struthers AD. Urate predicts subsequent cardiac death in stroke survivors. Eur Heart J 2002; 23: 788–793.

16. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746–751.
17. Doehner W, Schoene N, Rauchhaus M, Leyva-leon F, Pavitt D, Reaveley D et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105: 2619–2624.

18. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858–865.

19. Mustard JF, Murphy EA, Ogryzlo MA, Smythe HA. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J 1996; 89: 1207–1211.

20. Newland H. Hyperuricemia in coronary, cerebral and peripheral arterial disease: an explanation. Med Hypotheses 1975; 1: 152–155.

21. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16(12): 3553–3562.

22. Cannon CP, Greenberg BH. Risk stratification and prognostic factors in the post-myocardial infarction patient. Am J Cardiol 2008; 102: 13–20.

23. Burack RC, Keller JB, Higgins MW. Cardiovascular risk factors and obesity. J Chronic Dis 1985; 38: 865–872.

24. Dzielak DJ, Kivilgn SD. Emerging concepts in cardiovascular disease. Exp Opin Invest Drugs 1998; 7: 85–89.

25. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78: 147–153.

26. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635–639.

27. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7–13.

28. Liese AD, Hense HW, Lo¨wel H, Do¨ring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. Epidemiology 1999; 10: 391–397.

29. Moriaty JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000; 10: 136–143.

30. Verdecchia P, Schillaci G, Reboldi GP, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA Study. Hypertension 2000; 36: 1072–1078.

31. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfhann G, Lakkas HM, Timo A et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. A Prospective Cohort Study. Arch Intern Med 2004; 164: 1546–1551.

32. Allison TG. Coronary heart disease epidemiology. In: Murphy JG, Lloyd MA (eds). Mayo clinic cardiology. 3rd edn. Rochester (MN): Mayo Clinic Scientific Press, 2007: 687–693.

33. Dunkelgrun M, Welten GM, Goei D, Winkel TA, Schouten O, van Domburg RT et al. Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery. Am J Cardiol 2008; 102: 797–801.

34. Brodov Y, Chouraqui P, Goldenberg I, Boyko V, Mandelzweig L, Behar S. Serum uric acid for risk stratification of patients with coronary artery disease. Cardiology 2009; 114: 300–305.

35. Jularattanaporn V, Krittayaphong R, Boonyasirinant T, Udol K, Udompunurak S. Prevalence of hyperuricemia in Thai patients with acute coronary syndrome. Thai Heart J 2008; 21: 86–92.

36. Baruah M, Nath CK, Chaudhury B, Devi R, Ivvala AS. A study of serum uric acid and C-reactive protein in acute myocardial infarction. International Journal of Basic Medical Sciences and Pharmacy (IJBMSP) 2012; 2: 21–24.

37. Cheng-biao L, Lun-kuan WU, Ai-zhong J. Relationship between serum level of uric acid and acute coronary syndromes [Abstract]. Journal of Clinical and Experimental Medicine 2009; Issue 6: 77, 79

38. Nadkar MY, Jain VI. Serum uric acid in acute myocardial infarction. J Assoc Physicians India 2008; 56: 759–762.

39. Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Res Ther 2011; 13: 66.

40. Chen L, Li X, Qiao W, Ying Z, Qin Y, Wang Y et al. Serum uric acid in patients with acute ST-elevation myocardial infarction. World J Emerg Med 2012; 3(1): 35–39.

41. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 2005; 96: 489–495.

42. Kaya MG, Uyarel H, Akpek M, Kalay N, Erjlene M, Ayhan...
E et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2012; 109(4): 486–491.

43. Wu Y, Li M, Li J, Luo Y, Xing Y, Hu D. Elevated serum uric acid level as a predictor for cardiovascular and all-cause mortality in Chinese patients with high cardiovascular risk. J Geriatr Cardiol 2008; 5: 15–20.

44. Bae JH, Hyun DW, Kwon TG, Yoon HJ, Lerman A, Rihal CS. Serum uric acid is associated with cardiovascular events in patients with coronary artery disease. Korean Circulation J 2007; 37: 161–166.

45. Dharma S, Siswanto BB, Soerianata S, Wardeh AJ, Jukema JW. Serum uric acid as an independent predictor of cardiovascular event in patients with acute ST elevation myocardial infarction. J Clinic Experiment Cardiol 2012; S5:005. doi:10.4172/2155-9880.S5-005.

46. Poullis M. Serum uric acid and cardiovascular disease risk. Annals of Internal Medicine 2000; 132: 591.

47. Car S, Trkulja V. Higher serum uric acid on admission is associated with higher short-term mortality and poorer long-term survival after myocardial infarction: retrospective prognostic study. Croat Med J 2009; 50: 559–566.